H. Lundbeck, new pharmaceutical candidate in Lundbeck’s pipeline

Lundbeck has initiated phase I clinical trials with the pharmaceutical candidate Lu AA44608 to investigate safety, tolerability and the pharmacokinetic profile of the compound in humans.